Technology | January 09, 2012

SPECT System Receives FDA Clearance, Offers More Affordable Nuclear Medicine Solution

January 9, 2012 – GE Healthcare announced the Brivo NM615 has received clearance from the U.S. Food and Drug Administration (FDA).  An advanced single-head nuclear medicine gamma camera with single photon emission computed tomography (SPECT) capability, the system gives doctors the ability to lower injected patient dose by as much as 50 percent of those of standard nuclear medicine scanning protocols, or the potential for patients to spend less time on the table during exams, without compromising image quality. Made possible through GE’s detector design and evolution technology, this single-head system has the ability to achieve shortened scan times rivaling a dual-head system. 

GE Healthcare Brivo NM615 is engineered to help accommodate more patients than earlier GE nuclear medicine systems. With its 28 inch wide bore and table capable of handling patients up to 500 pounds , the Brivo NM615 provides access to a wide variety of patient sizes. The system can also be upgraded on site to the GE Healthcare Discovery NM630 or the Discovery NM/CT 670 SPECT/CT (computed tomograph) hybrid systems through on-site hardware changes.   As a result, Brivo NM615 may protect the initial investment by expanding the ability to serve patients well into the future at faster speeds and with SPECT/CT hybrid scanning capability.

The Elite NXT detector enables exceptional image quality and is designed to offer outstanding SPECT resolution and exceptional contrast for impressive image quality.  Ultra-thin design and auto-body contouring minimize the distance between the patient and the detectors for excellent resolution while SPECT-optimized collimators and the exceptionally high count rate enable extremely precise event detection.

In institutions and centers with high patient volumes, Brivo NM615 may provide an affordable solution to help clinicians increase capacity without compromising image quality; and due to the simple upgrade path, physicians facing budget constraints can choose the solution that meets their needs.

Shorter acquisition times and dose reduction capabilities are possible with the Brivo NM615 system only when used in combination with the relevant features offered on the Xeleris 3 processing and review workstation.

 Brivo NM615 can be used with the advanced Xeleris workstation, which integrates new and existing nuclear medicine equipment, including GE and non-GE devices, and is designed to provide consistent results and enhanced workflow. Xeleris can keep clinicians connected to images and applications from PACS and PCs within their institution and remotely.

For more information: www.gehealthcare.com  

 

Related Content

PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
Novel PET Imaging Method Could Track and Guide Type 1 Diabetes Therapy
News | PET Imaging | August 03, 2018
Researchers have discovered a new nuclear medicine test that could improve care of patients with type 1 diabetes. The...
Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
Overlay Init